Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age60+
SponsorPerceive Biotherapeutics, Inc.
About this trial
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Eligibility criteria
Qualifiers
Are ≥60 years of age at the time of consent.
Are willing and able to understand and provide written informed consent.
Are willing and able to return for scheduled treatment and follow-up examinations.
Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
Disqualifiers
Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
Additional Systemic, Ocular, and Genetic Exclusion Criteria.
Trial design
Treatments tested in this trial
- VOY-101
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
11Australia
Sydney Retina Clinic and Day Surgery2000, SydneyNew South Wales, Australia
Cerulea Clinical Trials3002, East MelbourneVictoria, Australia
Israel
Rambam Medical Center Haifa Israel
Tel-Aviv Sourasky Medical Center, Ophthalmology Division64239, Tel Aviv Israel
Sponsors and collaborators
Perceive Biotherapeutics, Inc.
Lead sponsor
Source ClinicalTrials.gov